Clinical trials: Severe Allergic Asthma
Asthma Acute, Exacerbation of Allergic Asthma
Nebulized Ketamine for Severe Asthma Attacks in Children
This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy.
- Trial name
- NCT07728851
- Testing
- Ketamine (1 mg/kg)
- Where
- Oman
- Volunteers
- 60 people
- Sponsor
- Sultan Qaboos University
Severe Asthma, Asthma in Children
Severe Eosinophilic Asthma Phenotypes During Childhood Have Various Origins
Study of the clinical evolution at 10 years of children from the SAMP cohort (severe asthma, eosinophilic or not, allergic or not) in order to understand the different possible evolutions of these phenotypes at different ages.
- Trial name
- SAMP 2 (NCT05762627)
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Asthma
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment.
- Trial name
- NCT00109200
- Testing
- Xolair (omalizumab)
- Sponsor
- Genentech, Inc.
Asthma
A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy
This study has the objective of providing compassionate use access to omalizumab (Xolair) and to evaluate the Safety of Xolair in subjects with severe allergic asthma who remain symptomatic despite optimal therapy according to…
- Trial name
- NCT00639691
- Testing
- omalizumab
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Moderate to Severe Allergic Asthma
Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma
The study was designed to collect data about inadequately controlled moderate to severe allergic asthma in subjects 6 to < 12 years of age, managed in a real-world setting.
- Trial name
- NCT01362621
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 474 people
- Sponsor
- Novartis Pharmaceuticals
Intrinsic Asthma, Allergic Asthma
The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children
The aim of investigator´s clinical trial is to investigate 52 patients aged three to five years with viral-induced asthma and 52 patients aged three to five years with allergic asthma.
- Conditions
- Intrinsic Asthma, Allergic Asthma, Allergy, Bronchial Hyperresponsiveness
- Trial name
- BHR (NCT01144910)
- Testing
- methacholine challenge test
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Asthma
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with…
- Trial name
- PROSE (NCT01430403)
- Testing
- Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS)
- Where
- 8 sites in United States
- Volunteers
- 478 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Lung Disease
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.
- Trial name
- NCT00139152
- Testing
- Xolair
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Creighton University
Asthma
Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma
This study investigated asthma-related quality of life in Brazilian patients using omalizumab.
- Trial name
- NCT00567476
- Testing
- Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA)
- Where
- Brazil
- Volunteers
- 116 people
- Sponsor
- Novartis
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Laminar Airflow in Severe Asthma for Exacerbation Reduction
To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with…
- Trial name
- LASER (NCT03058497)
- Testing
- Temperature-Controlled Laminar Airflow Device (Airsonett®)
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Portsmouth Hospitals NHS Trust
Asthma
Laminar Airflow in Severe Asthma for Exacerbation Reduction - 48 Month Follow-up.
Temperature-controlled Laminar Airflow (TLA) treatment delivered by the Airsonett treatment device is a new treatment for patients with allergic asthma.
- Trial name
- LASER-48 (NCT02813811)
- Where
- United Kingdom
- Volunteers
- 77 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Severe Asthma
3TR Asthma Biologics Cohort (ABC) Study
The 3TR-ABC study is a multicentre observational prospective cohort study platform that follows patients with severe asthma from the start of biological therapy and three years onwards.
- Trial name
- 3TR-ABC (NCT06126692)
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Allergic Asthma
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
The combined treatment of anti-IgE monoclonal antibody and standardized allergen immunotherapy has good efficacy and safety in allergic diseases.
- Trial name
- NCT06771934
- Testing
- Allergen-specific immunotherapy(AIT), omalizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qianfoshan Hospital